Abstract 264P
Background
Cancer-related cognitive impairment (CRCI), affecting up to 80% of breast cancer (BC) patients, manifests in various cognitive domains such as learning, memory, and concentration. The hippocampus, crucial for these cognitive processes and known to retain its neurogenesis capacity throughout adulthood, is susceptible to morphological alterations due to BC treatment. Recent research highlights the link between physical exercise and neurogenesis. This study aims to investigate CRCI and the potential effects of high-intensity interval training (HIIT) on learning, memory, and concentration function, as well as brain morphology in BC patients undergoing treatment.
Methods
This randomized (1:1) controlled trial allocated early-stage BC patients to either a HIIT intervention group (IG) or a control group (CG). The intervention involved a 12-month supervised HIIT program tailored through cardio-pulmonary exercise testing. Learning, memory, and concentration function were assessed using the California Verbal Learning Test (CVLT) alongside the Wechsler Memory Scale (WMS). Hippocampal volume was evaluated with MRI-based free surfer analysis. Assessments were conducted at baseline and after 12 months.
Results
A total of 69 patients (mean age 50.67 years, SD 10.55; 98.5% female) were recruited. The analysis showed no statistically significant changes in total hippocampal volume in either group (IG: p = 0.25 and p = 0.39; CG: p = 0.25 and p = 0.33). Similarly, no significant changes were observed in the CVLT scores for both groups (IG: p = 0.102; CG: p = 0.059). However, compared to the CG, the IG exhibited significant improvements in the WMS (p < 0.05).
Conclusions
Assessing CRCI in BC patients is challenging. Despite a multimodal approach, we couldn't objectify structural or functional adverse effects on specific cognitive subdomains. Although HIIT exercise during chemotherapy didn't notably impact learning and memory, it did enhance concentration over time. This might suggest that cognitive function in BC patients benefits from exercising.
Clinical trial identification
NCT04789187. Registered on 09 March 2021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Verein zur Forschungsförderung der Krebshilfe OÖ.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - Relationship between initial tumor burden and the probability of pathological complete response within molecular subtypes of early breast cancer treated with neoadjuvant chemotherapy
Presenter: Nicolas Roussot
Session: Poster session 14
260P - Impact of HER2-low status on clinicopathological characteristics and pathological complete response in luminal and triple-negative early breast cancer
Presenter: Katarzyna Pogoda
Session: Poster session 14
261P - Subtyping of residual disease (RD) following neoadjuvant chemotherapy (NACT) for triple negative breast cancer (TNBC): Evolution and prognostic impact
Presenter: Isabel Echavarria Diaz-Guardamino
Session: Poster session 14
262P - Predictive clinico-biological factors of toxicity associated to neo-adjuvant chemo- immunotherapy in early-stage triple-negative breast cancer
Presenter: Elsa Volant
Session: Poster session 14
263P - Association between clinicopathological characteristics and pathological complete response in patients with triple negative breast cancer treated by neoadjuvant chemo-immunotherapy
Presenter: Clara Helal
Session: Poster session 14
265P - Association of clinical benefit of adjuvant capecitabine and RCB class in triple negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy
Presenter: Shinyoung Lee
Session: Poster session 14
266P - Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial
Presenter: Guillermo Villacampa
Session: Poster session 14
267P - The tumour microenvironment influences long-term tamoxifen treatment response in breast cancer patients
Presenter: Paula Camargo Romera
Session: Poster session 14
268P - Impact of B cell and plasma cell infiltration on survival in early-stage breast cancer (BC) without recurrence
Presenter: Laura Angelats
Session: Poster session 14
269P - Her2-low/HRR proficient early triple negative breast cancer is characterized by good prognosis
Presenter: Benedetta Pellegrino
Session: Poster session 14